In this edition:
ADRIATIC: consolidation durvalumab in limited-stage SCLC
LAURA: Osimertinib after definitive CRT in unresectable, stage III, EGFRm NSCLC
REACH PC: telehealth vs. in-person early palliative care for advanced NSCLC
Lorlatinib vs. crizotinib in treatment-naïve, advanced, ALK+ NSCLC
ADAURA: MRD analysis of adjuvant osimertinib in EGFRm NSCLC
KRYSTAL-12: adagrasib vs. docetaxel in advanced, KRAS G1C2m NSCLC
CodeBreaK 101: sotorasib + carboplatin + pemetrexed in advanced, KRAS G1C2m NSCLC
CheckMate 816: 4-year update of neoadjuvant nivolumab + chemotherapy in resectable NSCLC
BEAT-meso: bevacizumab + chemotherapy ± atezolizumab in MPM
EVOKE-01: sacituzumab govitecan vs. docetaxel in previously treated, metastatic NSCLC
Please login below to download this issue (PDF)